Pharma/fine chemicals roundup—7 May
8:54 AM MDT | May 7, 2013 | By DEEPTI RAMESH
Teva’s API business reports fall in sales
The active pharmaceutical ingredient (API) business of Teva Pharmaceutical Industries (Petaḥ Tiqwa, Israel), recorded a 6.5% fall in sales in the first quarter compared with the year-ago quarter, to $186 million. Teva has the largest API business in the world in terms of sales.
Vertellus upgrades Belgium facility for API niacin manufacture
Vertellus Specialties (Indianapolis) says that its facility at Antwerp has completed capital and other upgrades for the manufacture of niacin, or nicotinic acid, for pharmaceutical use. The plant has been producing niacin and niacinamide for nearly 30 years and has supplied the ingredient for food applications as well as agricultural needs. Vertellus completed projects last year to upgrade the facility to meet stringent guidelines necessary to be fully compliant with cGMP in manufacture of an active pharmaceutical ingredient and has been inspected and deemed acceptable by FDA, Vertellus says.
Cambrex reports rise in profits and sales
Cambrex (East Rutherford, NJ) reports a 58.6% increase in net profits for the first quarter, ended 31 March, compared with the year-ago period, to $11.16 million. First-quarter sales increased 5.7%, to $74.58 million, including a favorable impact of foreign exchange of 1%. This rise was primarily due to higher custom development sales related to clinical-phase projects and higher sales of certain active pharmaceutical ingredients for branded commercial products, Cambrex says.
EMA announces details of planned reorganization
The European Medicines Agency (EMA; London) has announced the first details of its planned reorganization. The main high-level changes are the replacement of the current two units dealing with medicines for human use with four divisions focused on support to the R&D phase; medicines evaluation and life-cycle management; procedure management and business data; and inspections and pharmacovigilance. The new organizational structure is expected to take effect in the beginning of August. The full structure will be implemented over a period of 18 months. EMA is a decentralized agency of the European Union and is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.
Aesica partners with University of Nottingham to develop amide chemical synthesis technique
Aesica Pharmaceuticals (Newcastle upon Tyne, UK) says it has entered into a partnership with the University of Nottingham (Nottingham, UK) for the commercial development of alternative methods in amide bond synthesis. Amide bond formation is fundamental in pharmaceutical manufacturing. The partnership’s aim is to revolutionize traditional amide formation techniques by generating alternative methods for amide bond formation, which will be more eco-friendly and chemically versatile. “Since realizing the initial use of our coupling agent in 2005, one of our goals has been to see this novel technology used in larger-scale industrial environments. We look forward to collaborating with Aesica and seeing the full commercial potential of this novel technology in API manufacture,” says Simon Woodward, professor of synthetic organic chemistry at the University of Nottingham. This new amide production technology “will enable cheaper and simpler routes to market for many compounds,” says Barrie Rhodes, director of technology development at Aesica.
Connect with IHS Chemical Week
Our related sites